JP2025512749A - 感染症の新しい治療法 - Google Patents

感染症の新しい治療法 Download PDF

Info

Publication number
JP2025512749A
JP2025512749A JP2024554877A JP2024554877A JP2025512749A JP 2025512749 A JP2025512749 A JP 2025512749A JP 2024554877 A JP2024554877 A JP 2024554877A JP 2024554877 A JP2024554877 A JP 2024554877A JP 2025512749 A JP2025512749 A JP 2025512749A
Authority
JP
Japan
Prior art keywords
peptide
angptl4
amino acid
seq
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024554877A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025512749A5 (https=
Inventor
ブルドゥルース，サンドリーヌ
ジヴェリ，シャゾン
グエネック，ロイク ル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut National de la Sante et de la Recherche Medicale INSERM
Universite Paris Cite
Original Assignee
Institut National de la Sante et de la Recherche Medicale INSERM
Universite Paris Cite
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut National de la Sante et de la Recherche Medicale INSERM, Universite Paris Cite filed Critical Institut National de la Sante et de la Recherche Medicale INSERM
Publication of JP2025512749A publication Critical patent/JP2025512749A/ja
Publication of JP2025512749A5 publication Critical patent/JP2025512749A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/515—Angiogenesic factors; Angiogenin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Vascular Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2024554877A 2022-03-16 2023-03-15 感染症の新しい治療法 Pending JP2025512749A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP22305312 2022-03-16
EP22305312.5 2022-03-16
PCT/EP2023/056642 WO2023175022A1 (en) 2022-03-16 2023-03-15 New method to treat infectious diseases

Publications (2)

Publication Number Publication Date
JP2025512749A true JP2025512749A (ja) 2025-04-22
JP2025512749A5 JP2025512749A5 (https=) 2026-03-13

Family

ID=81324956

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024554877A Pending JP2025512749A (ja) 2022-03-16 2023-03-15 感染症の新しい治療法

Country Status (6)

Country Link
US (1) US20250163116A1 (https=)
EP (1) EP4493590A1 (https=)
JP (1) JP2025512749A (https=)
KR (1) KR20240159852A (https=)
CN (1) CN119053620A (https=)
WO (1) WO2023175022A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2023219197A1 (en) * 2022-02-14 2024-08-22 Sumant Singh CHUGH Methods of treating a cytokine storm related disease with recombinant mutated human angiopoietin-like 4
WO2025247922A1 (en) * 2024-05-28 2025-12-04 Institut National de la Santé et de la Recherche Médicale Use of the recombinant fibrinogen-like domain of angiopoietin-like 4 for treating sepsis capillary leak syndrome

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU643427B2 (en) 1988-10-31 1993-11-18 Immunex Corporation Interleukin-4 receptors
WO1991018982A1 (en) 1990-06-05 1991-12-12 Immunex Corporation Type ii interleukin-1 receptors
US6074849A (en) 1995-07-19 2000-06-13 Genetics Institute, Inc. Polynucleotides encoding human CTLA-8 related proteins
US6569645B2 (en) 1999-05-14 2003-05-27 Genentech, Inc. IL-17 homologous polypeptides and therapeutic uses thereof
US6579520B2 (en) 1998-05-15 2003-06-17 Genentech, Inc. IL-17 related mammalian cytokine polypeptides (IL-17E)
FR2827866B1 (fr) 2001-07-27 2004-12-10 Pasteur Institut Peptides synthetiques ou naturels liant la proteine phosphatase 2a, methode d'identification et utilisations
WO2004011595A2 (fr) 2002-07-26 2004-02-05 Institut Pasteur Vecteurs destines au transfert de molecules d'interet dans des cellules cibles
WO2011080132A2 (en) 2009-12-17 2011-07-07 Katholieke Universiteit Leuven, K.U. Leuven R&D Compounds, compositions and methods for controlling biofilms
WO2016020880A2 (en) * 2014-08-07 2016-02-11 Novartis Ag Angiopoietin-like 4 antibodies and methods of use
WO2016020882A2 (en) * 2014-08-07 2016-02-11 Novartis Ag Angiopoetin-like 4 (angptl4) antibodies and methods of use
US11446398B2 (en) * 2016-04-11 2022-09-20 Obsidian Therapeutics, Inc. Regulated biocircuit systems

Also Published As

Publication number Publication date
EP4493590A1 (en) 2025-01-22
US20250163116A1 (en) 2025-05-22
KR20240159852A (ko) 2024-11-06
WO2023175022A1 (en) 2023-09-21
CN119053620A (zh) 2024-11-29

Similar Documents

Publication Publication Date Title
US12134640B2 (en) Polypeptides and medical uses thereof
JP6466376B2 (ja) 鉄恒常性を制御するための組成物およびそれを用いる方法
US20240092867A1 (en) Methods and compositions for the treatment of wounds
JP2025512749A (ja) 感染症の新しい治療法
JP2016526020A (ja) 抗菌性ペプチド
JP7384672B2 (ja) Ｃ末端ｃｄｎｆ断片及びｃ末端ｍａｎｆ断片、それらを含む医薬組成物、並びにそれらの使用
US10889619B2 (en) Methods for treating cancer
Cárdenas-Martínez et al. Effects of substituting arginine by lysine in bovine lactoferricin derived peptides: pursuing production lower costs, lower hemolysis, and sustained antimicrobial activity
US7824691B2 (en) Use of RIP in treating staphylococcus aureus infections
US12479895B2 (en) C-terminal CDNF and MANF fragments, pharmaceutical compositions comprising same and uses thereof
JP2022526978A (ja) ヒト血清の存在下でシュードモナス・エルギノーサに対する殺菌活性を有する溶解素及びその誘導体
JP6042106B2 (ja) メチオニン・スルホキシドを含む新規ポリペプチド
US20230095144A1 (en) Amyloid inhibitory peptides
WO2018206732A9 (en) MEANS AND METHODS OF TREATING BACTERIAL INFECTIONS
KR20210151188A (ko) 뼈 및 관절 감염증의 치료 및 예방 방법
KR20210141667A (ko) 감염성 심내막염의 치료 방법
US20150072922A1 (en) Rnase 7 antimicrobial peptides
US20250352614A1 (en) Peptide therapeutics for the treatment of cancer and uses thereof
JP2023526386A (ja) グラム陽性細菌に対して使用される修飾ＰｌｙＳｓ２溶解素及び抗生物質の組合せ
CN115209912A (zh) 肽组合物及其使用方法
US20160271220A1 (en) Compositions and methods for using and identifying antimicrobial agents

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260305

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20260305